Glucotrack Financials
This page shows Glucotrack (GCTK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
GlucoTrack’s externally financed cash burn dominates the model, with new capital repeatedly replacing outflows instead of self-funding operations.
From FY2023 to FY2025, operating cash burn rose from-$6.6M to-$15.2M , making the business increasingly dependent on outside funding. The reason FY2025 still ended with$7.4M of cash is that financing inflows over FY2023-FY2025 totaled about$39.5M , and the close match between operating loss and cash burn shows those losses were consuming real cash rather than being cushioned by non-cash accounting.
R&D remained the largest expense at
Liquidity tightened even after a balance-sheet reset: the current ratio fell to 1.6x in FY2025 from 4.5x in FY2024 as near-term obligations grew faster than liquid assets. At the same time, equity swung back positive to
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Glucotrack's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Glucotrack carries a low D/E ratio of 1.77, meaning only $1.77 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 66/100, indicating a strong balance sheet with room for future borrowing.
Glucotrack's current ratio of 1.61 is below the typical benchmark, resulting in a score of 28/100. However, the company holds substantial cash reserves (155% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.
Glucotrack generates a -685.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
Glucotrack passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Glucotrack generates $0.79 in operating cash flow (-$15.2M OCF vs -$19.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Glucotrack's EBITDA was -$16.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 10.6% from the prior year.
Glucotrack reported -$19.4M in net income in fiscal year 2025. This represents an increase of 14.2% from the prior year.
Glucotrack earned $31.22 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 99.2% from the prior year.
Cash & Balance Sheet
Glucotrack generated -$15.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 21.8% from the prior year.
Glucotrack held $7.4M in cash against $0 in long-term debt as of fiscal year 2025.
Glucotrack had 910,688 shares outstanding in fiscal year 2025. This represents an increase of 6691.6% from the prior year.
Margins & Returns
Glucotrack's ROE was -685.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Glucotrack invested $9.8M in research and development in fiscal year 2025. This represents an increase of 3.3% from the prior year.
Glucotrack invested $96K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 7.7% from the prior year.
GCTK Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $3.2M+0.5% | $3.1M+68.4% | $1.9M | N/A | $2.1M | N/A | $2.1M |
| SG&A Expenses | N/A | $1.0M-30.1% | $1.5M-2.3% | $1.5M | N/A | $1.1M+32.5% | $802K+9.4% | $733K |
| Operating Income | N/A | -$4.3M+10.2% | -$4.8M-37.1% | -$3.5M | N/A | -$3.3M | N/A | -$3.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $5K | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$4.2M+12.3% | -$4.8M+30.4% | -$6.8M | N/A | N/A | N/A | -$2.9M |
| EPS (Diluted) | N/A | $4.64-51.8% | $9.62 | $-0.67 | N/A | $1092.00+11.0% | $984.00 | $-11.73 |
GCTK Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.8M-5.5% | $8.3M-18.8% | $10.2M+6.2% | $9.6M+62.0% | $5.9M+618.2% | $826K+35.9% | $608K-71.1% | $2.1M |
| Current Assets | $7.7M-5.4% | $8.1M-19.6% | $10.1M+6.6% | $9.5M+63.9% | $5.8M+798.4% | $642K+45.2% | $442K-77.2% | $1.9M |
| Cash & Equivalents | $7.4M-6.2% | $7.9M-17.6% | $9.6M+5.0% | $9.1M+62.0% | $5.6M+1523.4% | $346K+117.6% | $159K-89.4% | $1.5M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $5.0M-9.6% | $5.5M+66.3% | $3.3M+41.5% | $2.4M-87.6% | $18.9M+290.5% | $4.8M+24.4% | $3.9M+125.3% | $1.7M |
| Current Liabilities | $4.8M-9.9% | $5.3M+71.7% | $3.1M+58.2% | $1.9M+52.9% | $1.3M-72.3% | $4.6M+26.0% | $3.7M+147.0% | $1.5M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $2.8M+2.8% | $2.8M-60.0% | $6.9M-5.3% | $7.3M+155.9% | -$13.0M-223.2% | -$4.0M-22.3% | -$3.3M-977.1% | $375K |
| Retained Earnings | -$151.8M-2.4% | -$148.2M-2.9% | -$144.0M-3.4% | -$139.3M-5.2% | -$132.4M-8.2% | -$122.4M-4.3% | -$117.3M-4.0% | -$112.8M |
GCTK Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.9M+14.8% | -$4.6M-23.4% | -$3.7M-27.4% | -$2.9M+16.0% | -$3.5M | N/A | -$1.9M+35.2% | -$2.9M |
| Capital Expenditures | $20K-70.1% | $67K | $0-100.0% | $9K | $0-100.0% | $33K+175.0% | $12K-79.7% | $59K |
| Free Cash Flow | -$4.0M+15.6% | -$4.7M-25.2% | -$3.7M-27.0% | -$2.9M+15.7% | -$3.5M | N/A | -$1.9M+36.1% | -$3.0M |
| Investing Cash Flow | -$20K+70.1% | -$67K | $0+100.0% | -$9K | $0+100.0% | -$33K-175.0% | -$12K+79.7% | -$59K |
| Financing Cash Flow | $3.5M+16.7% | $3.0M-28.0% | $4.2M-34.9% | $6.4M-27.2% | $8.8M | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
GCTK Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -151.6%-82.5pp | -69.1%+24.9pp | -94.1% | N/A | N/A | N/A | -780.5% |
| Return on Assets | N/A | -50.3%-3.7pp | -46.6%+24.5pp | -71.1% | N/A | N/A | N/A | -139.0% |
| Current Ratio | 1.61+0.1 | 1.53-1.7 | 3.27-1.6 | 4.85+0.3 | 4.52+4.4 | 0.14+0.0 | 0.12-1.2 | 1.31 |
| Debt-to-Equity | 1.77-0.2 | 2.01+1.5 | 0.48+0.2 | 0.32+1.8 | -1.46-0.3 | -1.21-0.0 | -1.18-5.8 | 4.61 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Glucotrack profitable?
No, Glucotrack (GCTK) reported a net income of -$19.4M in fiscal year 2025.
What is Glucotrack's EBITDA?
Glucotrack (GCTK) had EBITDA of -$16.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Glucotrack's return on equity (ROE)?
Glucotrack (GCTK) has a return on equity of -685.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Glucotrack's free cash flow?
Glucotrack (GCTK) generated -$15.3M in free cash flow during fiscal year 2025. This represents a -21.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Glucotrack's operating cash flow?
Glucotrack (GCTK) generated -$15.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Glucotrack's total assets?
Glucotrack (GCTK) had $7.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Glucotrack's capital expenditures?
Glucotrack (GCTK) invested $96K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Glucotrack spend on research and development?
Glucotrack (GCTK) invested $9.8M in research and development during fiscal year 2025.
What is Glucotrack's current ratio?
Glucotrack (GCTK) had a current ratio of 1.61 as of fiscal year 2025, which is generally considered healthy.
What is Glucotrack's debt-to-equity ratio?
Glucotrack (GCTK) had a debt-to-equity ratio of 1.77 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Glucotrack's return on assets (ROA)?
Glucotrack (GCTK) had a return on assets of -247.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Glucotrack's cash runway?
Based on fiscal year 2025 data, Glucotrack (GCTK) had $7.4M in cash against an annual operating cash burn of $15.2M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Glucotrack's Piotroski F-Score?
Glucotrack (GCTK) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Glucotrack's earnings high quality?
Glucotrack (GCTK) has an earnings quality ratio of 0.79x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Glucotrack?
Glucotrack (GCTK) scores 16 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.